RIFAXIMINA E SIMVASTATINA MIGLIORANO IL PROFILO PLASMATICO DEI METABOLITI IN CORSO DI CIRROSI SCOMPENSATA. DA “Hepatology Communications” (FREE).

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoria

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis Elisa Pose, et al. Abstract Patients with decompensated cirrhosis, particularly those with acute‐on‐chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma…

RIFAXIMINA + LUBIPROSTONE: RIDUZIONE DELLA FIBROSI VIA RIPARAZIONE DELLA BARRIERA MUCOSA. UN MODELLO ANIMALE DA SEGUIRE

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA DEI PROBIOTICI, Senza categoria

Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis Masahide Enomoto et al. Abstract Background Although gut-derived lipopolysaccharide (LPS) affects the progression of non-alcoholic steatohepatitis (NASH) pathogenesis, few studies have focused on this relationship to develop treatments for NASH. Aims To explore the effects of combination with rifaximin…

STANDARD CONSIGLIATO PER I TRIAL SUL CANCRO DEL PANCREAS , RESECABILE, O BORDERLINE RESECABILE. UN IMPORTANTE CONSENSUS STATEMENT DA “JAMA SURGERY” .

CHIRURGIA, GASTROENTEROLOGIA, METODOLOGIA, PANCREAS E VIE BILIARI, Senza categoria

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). A Systematic Review and Delphi Consensus Statement. Esther N. Pijnappel et al. Abstract Importance  Pancreatic cancer is the third most common cause of cancer death; however, randomized clinical trials (RCTs) of survival in patients with resectable pancreatic cancer…

ULTIMA META-ANALISI SU RIFAXIMINA ED ENCEFALOPATIA EPATICA . ABSTRACT DAL “J. OF HEPATOLOGY”. NNT = 5; participants = 969 PER OUTCOME REGRESSIONE ENCEFALOPATIA

CIRROSI EPATICA, ENCEFALOPATIA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoria

Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials Harry Demetrios Zacharias et al. SAT501 Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials Harry D Zacharias1, Jaclyn Yizhen Tan1, Fady Kamel1, Nina Kimer2, Lise Lotte Gluud2,…

IL COVID HA AUMENTATO TERRIBILMENTE LE DISEGUAGLIANZE. DA “NATURE” SEI GRAFICI IMPRESSIONANTI (FREE)

COVID19 - EVIDENCE, INTERNATIONAL SNAPSHOTS, REAL WORLD EVIDENCE, Senza categoria

How COVID has deepened inequality — in six stark graphics Saima May Sidik The shock waves of the COVID-19 pandemic have reverberated throughout the world. But the latest data reveal that the burden of COVID and its aftermath does not rest equally. In six graphics, Nature details how the pandemic has worsened existing inequalities and exposed others…

ATTENZIONE, URGENTE ! OCCORRE PASSARE ALLA “EBM PLUS”, O “EBM+” DOPO LA EPIDEMIA (FREE).

COVID19 - EVIDENCE, METODOLOGIA, REAL WORLD EVIDENCE

Adapt or die: how the pandemic made the shift from EBM to EBM+ more urgent Trisha Greenhalgh et al. Abstract Evidence-based medicine (EBM’s) traditional methods, especially randomised controlled trials (RCTs) and meta-analyses, along with risk-of-bias tools and checklists, have contributed significantly to the science of COVID-19. But these methods and tools were designed primarily to answer…